David B. Patteson
David, who joined Ampersand as an Operating Partner in 2015, serves on the Board of New England Peptide, and previously served as a Board member of Gyros Protein Technologies. He is Chairman/CEO of Adchim SAS, a life science instrument business. He served as CEO of Advion, sold to Bohui Innovation Technology in 2015. David also served as CEO of Advion BioSciences, a bioanalytical CRO business acquired by Quintiles Transnational in 2011, and CEO of Biotage, which was acquired by Pyrosequencing AB in 2003. David holds two separate B.S. degrees from The University of Richmond and Virginia Polytechnic Institute, and completed an International Management program through IMD in Lausanne, Switzerland.